Innovative Toxicity Assays of Pollutants, Therapeutics, and Drugs (STTR R41/R42) | Apply Online

Opportunity Summary:

The NIH grant opportunity "Innovative Toxicity Assays of Pollutants, Therapeutics, and Drugs (STTR R41/R42)" (Funding Opportunity Number PA 09 007) is aimed at helping small businesses, working in partnership with research institutions, create better ways to detect and predict toxic effects caused by a wide range of substances. The core idea is to move toxicity testing beyond traditional methods by supporting development, standardization, and validation of new assays and testing strategies that can more accurately identify organ-specific harm from chemicals, environmental pollutants, biologics, and therapeutic drugs. The opportunity is broad on purpose, covering both short-term (acute) and long-term (chronic) exposure scenarios, which matters because many real-world health effects emerge only after repeated or prolonged exposure.

A major focus is organ toxicity, with the FOA explicitly calling out many target systems. Projects can center on assays that measure or predict damage to the eye (ocular toxicity), skin (dermal toxicity), blood and blood-forming systems (hematotoxicity), heart (cardiotoxicity), gastrointestinal tract, liver (hepatotoxicity), kidneys (nephrotoxicity), ear and hearing-related pathways (ototoxicity), smell and olfactory function (including olfactory loss), bladder, nervous system (neurotoxicity), lungs (pulmonary toxicity), endocrine system (endocrine toxicity), and pancreatic beta cells (relevant to diabetes and metabolic disease). In practice, this means applicants can propose tools that flag early biomarkers of organ injury, assays that distinguish reversible from irreversible effects, or methods that better translate to human risk than older screening approaches.

Beyond organ toxicity, the FOA also encourages the creation and validation of new disease or response models in several areas: arthritis, convulsion, infection, and shock. This is a signal that NIH is interested not only in classic toxicity endpoints, but also in complex physiological states where toxic exposures or therapeutics can trigger systemic or syndrome-like outcomes. For applicants, that opens the door to model systems that replicate inflammatory cascades, immune dysregulation, neurological hyperexcitability, or hemodynamic collapse, so long as the work results in practical, validated tools that can be used for testing and decision-making.

The announcement strongly supports innovation in how toxicity is measured and predicted, especially approaches that can scale. High-throughput toxicity screening is highlighted, particularly when it uses molecular endpoints rather than relying only on late-stage tissue damage. The FOA explicitly encourages computational and "omics" driven approaches, including computer modeling, proteomics, genomics, and epigenomics, along with the development of virtual tissues. This points to interest in predictive modeling frameworks that can integrate large datasets, identify mechanistic signatures of toxicity, and potentially reduce the cost and time of screening large chemical libraries or drug candidates. It also aligns with a broader push in toxicology toward mechanism-based testing and more human-relevant predictive systems.

Another emphasized area is advanced model development, including 3-dimensional organ models for toxicity evaluation. That can include 3D cell culture systems, organotypic constructs, and other engineered tissue-like platforms intended to better represent how real organs respond to exposure compared with standard 2D cell cultures. The underlying goal is to improve predictive validity: assays that are not only novel, but also demonstrably reliable, reproducible, and meaningful for anticipating clinically relevant toxicity.

On the funding mechanism side, this is an STTR opportunity using the R41/R42 structure. That means it is specifically for small business concerns that will collaborate with a nonprofit research institution, with a formal partnership and defined work split between the small business and the research partner. The FOA allows Phase I, Phase II, and Fast Track applications. Phase I generally supports early proof-of-concept and feasibility work, Phase II supports further development and more extensive validation, and Fast Track is designed to combine Phase I and Phase II into a continuous application path when the plan and preliminary feasibility are strong enough.

This FOA also runs in parallel with a companion announcement of the same scientific scope for SBIR applicants (PA 09 006; R43/R44). The key takeaway is that NIH is offering two small-business pathways for essentially the same types of toxicity assay and model development projects, with STTR being the route that requires the formal research institution partnership structure.

Administratively, the opportunity was posted October 8, 2008, with an original and current closing date of September 7, 2009, and it was archived October 8, 2009. No cost sharing or matching is required. Eligibility is limited to small businesses, consistent with STTR rules. The opportunity is associated with multiple NIH program areas as reflected by the CFDA numbers listed, spanning environmental health and organ system research domains such as cardiovascular disease, arthritis and musculoskeletal/skin diseases, diabetes/digestive/kidney diseases, vision research, nursing research, and research related to deafness and communication disorders. Taken together, those align with the wide range of toxicity endpoints the FOA is trying to improve.

In plain terms, this grant opportunity was designed to push the field toward faster, more informative, and more predictive toxicity testing tools that small businesses can develop into broadly useful platforms. The emphasis is not just on creating a clever assay, but on building something standardized and validated enough that it can credibly inform toxicology screening, product development, and risk assessment across pharmaceuticals, biologics, and environmental chemicals.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Environment Food and Nutrition Health

Next opportunity: Innovative Toxicity Assays of Pollutants, Therapeutics, and Drugs (SBIR R43/R44)

Previous opportunity: NINDS Cooperative Program in Translational Research Small Business Awards (SBIR U44)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 007

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 007) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 007", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.